среда, 25 января 2017 г.

Possible liver injury added to label of Biogen MS drug

Possible liver injury added to label of Biogen MS drug


The prescribing label for Biogen Inc's big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury that could require hospitalization, the company said on Wednesday. Tecfidera, the world's top-selling oral MS treatment, accounts for about a third of Biogen revenue.



from Biotech News